LY3202626

low-dose CNS-penetrant BACE inhibitor

90% red. of CSF A_ in Ph. II at 9.2 mg / discont.

from opt. vs. CatD and dose red. of prior leads

Journal of Medicinal Chemistry

Eli Lilly, Indianapolis, US

6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase II of clinical trial against AlzheimerÕs disease in 2016.…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks